Therapeutics News and Research

RSS

Scientists discover a catalytic antibody that degrades a known appetite stimulant

The antibody works against the gastric hormone ghrelin (pronounced "grell-in"), which has been linked to weight gain and fat storage through its metabolic actions. These findings point towards a potentially novel treatment for obesity that would interfere directly with the some of the biological mechanisms determining weight.

28 Oct 2008

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

26 Oct 2008

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.

22 Oct 2008

Trius Therapeutics awarded $28 million to develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV

Trius Therapeutics, Inc., today announced the award of a $28 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, for the development of novel antibiotics directed against multiple Gram-negative bacterial pathogens.

22 Oct 2008

St. Jude Medical gets U.S. and European approval of Angio-Seal Evolution Vascular Closure Device

St. Jude Medical, Inc. has announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.

14 Oct 2008

New maturation inhibitor drugs may help solve HIV treatment conundrum

Since AIDS was first recognized in 1981, significant advances have been made in developing an effective arsenal of drugs to manage the disease and extend patients' lives.

13 Oct 2008

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

Vulnerable plaque may be easier to detect through optical coherence tomography

Research results indicate that optical coherence tomography (OCT), a newly evolving imaging method, may be the best tool available to detect vulnerable plaque in coronary arteries. The findings will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

12 Oct 2008

New devices used to reduce arterial occlusions, provide cardiac support

Research results highlighting three new devices used to reduce blockages in peripheral and coronary arteries and to provide cardiac support will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

12 Oct 2008

Study reveals that signs of heart disease are attributed to stress more frequently in women than men

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), found that coronary heart disease (CHD) symptoms presented in the context of a stressful life event were identified as psychogenic in origin when presented by women and organic in origin when presented by men. The study could help explain why there is often a delay in the assessment of women with heart disease.

12 Oct 2008

Olmesartan may reduce coronary artery plaque

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat high blood pressure, may play a role in reducing coronary plaque

12 Oct 2008

Scientists identify a molecule that coordinates the movement of cells

Even cells commute. To get from their birthplace to their work site, they sequentially attach to and detach from an elaborate track of exceptionally strong proteins known as the extracellular matrix. Now, in research to appear in the October 3 issue of Cell, scientists at Rockefeller University show that a molecule, called ACF7, helps regulate and power this movement from the inside - findings that could have implications for understanding how cancer cells metastasize.

2 Oct 2008

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.

30 Sep 2008

Arana files U.S. IND for lead anti-Inflammatory

Biotechnology company Arana Therapeutics Limited today announced it has submitted an Investigational New Drug application (IND) to the FDA (U.S. Food and Drug Administration) for the anti-inflammatory product ART621 in a rheumatoid arthritis (RA) indication.

29 Sep 2008

Arana updates inflammatory pipeline milestones

Biotechnology company Arana Therapeutics Limited today provided an update on the major inflammatory compounds in its drug development pipeline. As part of this update, Arana said it has developed a new antibody candidate ART123, targeting inflammatory diseases and it plans to start a Phase I clinical trial for age-related macular degeneration (AMD) candidate PMX53 in 2009.

21 Sep 2008

Scientists discover how to isolate cancer stem cells in tumors

After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning.

11 Sep 2008

Untapped potential of antidepressants for cancer

A comprehensive review of current scientific literature, published in the peer-reviewed journal ecancer, has suggested that antidepressants can help the human body fight cancer by boosting its own immune response, amongst other mechanisms.

11 Sep 2008

GlaxoSmithKline and Cellzome announce major strategic alliance

Cellzome Inc. and GlaxoSmithKline have announced the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

10 Sep 2008

'Black sheep protein' key to cancer cell death

A neglected member of an important family of proteins could boost the effectiveness of an exciting new group of cancer drugs - reveals a study in Cancer Cell.

8 Sep 2008

Merck Serono and Ablynx to jointly develop nanobodies

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has entered into an agreement with Ablynx, to co-discover and co-develop Nanobodies against two targets in oncology and immunology. The agreement includes an upfront cash payment to Ablynx of EUR10 million.

4 Sep 2008

Therapeutics News and Research

Scientists discover a catalytic antibody that degrades a known appetite stimulant

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

Trius Therapeutics awarded $28 million to develop novel drugs targeting bacterial DNA Gyrase and Topoisomerase IV

St. Jude Medical gets U.S. and European approval of Angio-Seal Evolution Vascular Closure Device

New maturation inhibitor drugs may help solve HIV treatment conundrum

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Vulnerable plaque may be easier to detect through optical coherence tomography

New devices used to reduce arterial occlusions, provide cardiac support

Study reveals that signs of heart disease are attributed to stress more frequently in women than men

Olmesartan may reduce coronary artery plaque

Scientists identify a molecule that coordinates the movement of cells

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Arana files U.S. IND for lead anti-Inflammatory

Arana updates inflammatory pipeline milestones

Scientists discover how to isolate cancer stem cells in tumors

Untapped potential of antidepressants for cancer

GlaxoSmithKline and Cellzome announce major strategic alliance

'Black sheep protein' key to cancer cell death

Merck Serono and Ablynx to jointly develop nanobodies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News